These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 33726685)

  • 1. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.
    Sung S; Al-Karaghouli M; Kalainy S; Cabrera Garcia L; Abraldes JG
    BMC Gastroenterol; 2021 Mar; 21(1):120. PubMed ID: 33726685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
    Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
    J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy.
    Muñoz AE; Pollarsky FD; Marino M; Cartier M; Vázquez H; Salgado P; Romero G
    World J Gastroenterol; 2021 Jul; 27(28):4639-4652. PubMed ID: 34366626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury.
    Muñoz AE; Pollarsky F; Marino M; Cartier M; Míguez C; Vázquez H; Álvarez D; Salgado P; Romero G
    Dig Dis Sci; 2021 Sep; 66(9):3199-3208. PubMed ID: 33033975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
    Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
    Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction potential between clarithromycin and individual statins-A systematic review.
    Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
    Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.
    Trias F; Pintó X; Corbella E; Suárez-Tembra M; Ruíz-García A; Díaz-Díaz JL; Sánchez-Ruíz-Granado E; Sarasa I; Martínez-Porqueras R; Rodríguez-Sánchez MA; Corbella X;
    Med Clin (Barc); 2022 Jun; 158(11):531-539. PubMed ID: 34517987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
    Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.